{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T03:22:48Z","timestamp":1794712968057,"version":"4.9.1"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01674-6","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:22:41Z","timestamp":1741184561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Breakthroughs in treatment for hematological malignancies: latest updates on molecular glue, PROTACs and RNA degraders from ASH 2024"],"prefix":"10.1186","volume":"18","author":[{"given":"Na","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpeng","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"1674_CR1","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/blood-2024-201221","volume":"144","author":"X 1 Dong","year":"2024","unstructured":"Dong X, et al. Potent in Vitro and in vivo efficacy of Hdz-C123A, a GSPT1 degrader-antibody Conjugate Targeting CD123 in Acute myeloid leukemia. Blood. 2024;144:156. https:\/\/doi.org\/10.1182\/blood-2024-201221.","journal-title":"Blood"},{"key":"1674_CR2","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1182\/blood-2024-209068","volume":"144","author":"S 2 Rauch","year":"2024","unstructured":"Rauch S, et al. Sky-1214, a small Molecule Splicing Modulator Targeting FANCL and Fanci, provides a new mechanism of Action Targeting multiple myeloma and Non-hodgkin\u2019s lymphoma. Blood. 2024;144:2784. https:\/\/doi.org\/10.1182\/blood-2024-209068.","journal-title":"Blood"},{"key":"1674_CR3","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1182\/blood-2024-199212","volume":"144","author":"JF 3 Seymour","year":"2024","unstructured":"Seymour JF, et al. Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory Waldenstr\u00f6m Macroglobulinemia: results from the phase 1 CaDAnCe-101 study. Blood. 2024;144:860. https:\/\/doi.org\/10.1182\/blood-2024-199212.","journal-title":"Blood"},{"key":"1674_CR4","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1182\/blood-2024-199116","volume":"144","author":"MC 4 Thompson","year":"2024","unstructured":"Thompson MC, et al. Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic Leukemia\/Small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study. Blood. 2024;144:885\u2013885. https:\/\/doi.org\/10.1182\/blood-2024-199116.","journal-title":"Blood"},{"key":"1674_CR5","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1182\/blood-2024-194839","volume":"144","author":"NN 5 Shah","year":"2024","unstructured":"Shah NN, et al. Efficacy and safety of the Bruton\u2019s tyrosine kinase (BTK) degrader NX-5948 in patients with Relapsed\/Refractory (R\/R) chronic lymphocytic leukemia (CLL): updated results from an ongoing phase 1a\/b study. Blood. 2024;144:884. https:\/\/doi.org\/10.1182\/blood-2024-194839.","journal-title":"Blood"},{"key":"1674_CR6","doi-asserted-by":"publisher","first-page":"44224421","DOI":"10.1182\/blood-2024-194009","volume":"144","author":"MT 6 Tees","year":"2024","unstructured":"Tees MT, et al. A phase 1 study of AC676, a novel BTK chimeric degrader, in patients with B-Cell malignancies. Blood. 2024;144:44224421. https:\/\/doi.org\/10.1182\/blood-2024-194009.","journal-title":"Blood"},{"key":"1674_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood-2024-210482","volume":"144","author":"S 7 Horwitz","year":"2024","unstructured":"Horwitz S, et al. Initial results of a phase 1 first-in-human study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, in patients with Non-hodgkin\u2019s lymphoma. Blood. 2024;144:467\u2013467. https:\/\/doi.org\/10.1182\/blood-2024-210482.","journal-title":"Blood"},{"key":"1674_CR8","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1182\/blood-2024-204255","volume":"144","author":"B 8 Dhakal","year":"2024","unstructured":"Dhakal B, et al. Initial results of a phase 1 first-in-human study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, with dexamethasone in patients with Relapsed\/Refractory multiple myeloma. Blood. 2024;144:3366\u20133366. https:\/\/doi.org\/10.1182\/blood-2024-204255.","journal-title":"Blood"},{"key":"1674_CR9","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1182\/blood-2024-210301","volume":"144","author":"T 9 Feldman","year":"2024","unstructured":"Feldman T, et al. Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a targeted protein degrader of STAT3, in patients with relapsed or refractory lymphomas, leukemia, and solid tumors. Blood. 2024;144:4433. https:\/\/doi.org\/10.1182\/blood-2024-210301. Safety.","journal-title":"Blood"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01674-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01674-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01674-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T14:22:42Z","timestamp":1741184562000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01674-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1674"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01674-6","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}